

# ASX Announcement

22 July 2025

## Amended Change of Director's Interest Notice

Cogstate Ltd (ASX:CGS) notes that a Change in Director's Interest Notice for Mr Bradley O'Connor ("Notice") was released to the ASX on 9 July 2025.

The Notice had a typographical error in the 'No. of securities held after change' with the correct calculation for the interest in No. 1 being 5,338,929.

Please find attached an Amended Notice, reflecting the correct total number of securities held.

This announcement was authorised for release by Cogstate Ltd CEO, Brad O'Connor.

---

### About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in the USA & Asia. For more information, please visit [www.cogstate.com](http://www.cogstate.com).

### For further information contact:

Brad O'Connor, Chief Executive Officer, [boconnor@cogstate.com](mailto:boconnor@cogstate.com)

# AMENDED Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Cogstate Limited</b>
<b>ABN</b>	<b>80 090 975 723</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Bradley O'Connor
<b>Date of last notice</b>	08 November 2024

### Part 1 – Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	<ol style="list-style-type: none"> <li>1. Direct</li> <li>2. Direct</li> <li>3. Indirect</li> <li>4. Direct</li> </ol>
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> <li>1. N/A</li> <li>2. N/A</li> <li>3. As beneficiary of O'Connor Superannuation Fund [registered holder: Ronnocob Pty Ltd &lt;O'Connor Superannuation Fund A/C&gt;</li> <li>4. N/A</li> </ol>
<b>Date of change</b>	09 July 2025
<b>No. of securities held prior to change</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares: 4,488,429</li> <li>2. Employee Options: 2,250,000</li> <li>3. Ordinary Shares: 949,673</li> <li>4. Performance Rights: 920,251</li> </ol>

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares</li> <li>2. Employee Options</li> <li>3. Ordinary Shares</li> <li>4. Performance Rights</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>1. 850,500 Ordinary Shares</li> <li>2. Nil</li> <li>3. Nil</li> <li>4. Nil</li> </ol>
<b>Number disposed</b>	<ol style="list-style-type: none"> <li>1. Nil</li> <li>2. 850,500 Employee Options</li> <li>3. Nil</li> <li>4. Nil</li> </ol>
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> <li>1. \$665,091</li> <li>2. N/A</li> <li>3. N/A</li> <li>4. N/A</li> </ol>
<b>No. of securities held after change</b>	<ol style="list-style-type: none"> <li>1. Ordinary Shares: <u>5,338,929</u>  <del>5,388,929</del></li> <li>2. Employee Options: 1,399,500</li> <li>3. Ordinary Shares: 949,673</li> <li>4. Performance Rights: 920,251</li> </ol>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	<ol style="list-style-type: none"> <li>1. Issue of shares upon exercise of employee options</li> <li>2. Exercise of employee options at \$0.782 exercise price</li> <li>3. N/A</li> <li>4. N/A</li> </ol>

---

+ See chapter 19 for defined terms.

For personal use only

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

+ See chapter 19 for defined terms.

For personal use only